Front Street Capital Management, Inc. Amgen Inc Transaction History

Front Street Capital Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$255.7 - $288.46 $10,739 - $12,115	-42 Reduced 9.03%	423 $122,000
Q3 2023 Nov 14, 2023	BUY	$218.65 - $271.46 $101,672 - $126,228	465 New	465 $125,000
Q1 2020 May 14, 2020	SELL	$182.24 - $241.7 $161,282 - $213,904	-885 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$189.21 - $243.2 $167,450 - $215,232	885 New	885 $213,000
Q2 2019 Aug 14, 2019	SELL	$166.7 - $195.41 $241,714 - $283,344	-1,450 Closed	0 $0
Q1 2019 May 01, 2019	SELL	$180.87 - $203.88 $4,521 - $5,097	-25 Reduced 1.69%	1,450 $275,000
Q4 2018 Feb 13, 2019	SELL	$178.4 - $208.25 $22,300 - $26,031	-125 Reduced 7.81%	1,475 $287,000
Q3 2018 Nov 13, 2018	SELL	$185.29 - $208.89 $21,308 - $24,022	-115 Reduced 6.71%	1,600 $332,000
Q2 2018 Aug 14, 2018	BUY	$166.05 - $186.51 $39,852 - $44,762	240 Added 16.27%	1,715 $317,000
Q4 2017 Feb 14, 2018	SELL	$168.79 - $188.59 $4,388 - $4,903	-26 Reduced 1.73%	1,475 $257,000
Q2 2017 Aug 08, 2017	BUY	N/A	1,501	1,501 $259,000

3,123

409M

7.56M

7.2M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $150B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Front Street Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Front Street Capital Management, Inc. with notifications on news.